Pasireotide for the Medical Management of Feline Hypersomatotropism

Article English OPEN
Scudder, C.J. ; Gostelow, R. ; Forcada, Y. ; Schmid, H.A. ; Church, D. ; Niessen, S.J.M. (2015)
  • Publisher: John Wiley and Sons Inc.
  • Journal: Journal of Veterinary Internal Medicine, volume 29, issue 4, pages 1,074-1,080 (issn: 0891-6640, eissn: 1939-1676)
  • Related identifiers: pmc: PMC4895359, doi: 10.1111/jvim.12608
  • Subject: Standard Article | Pituitary | Inhibition | Diabetes mellitus | Standard Articles | Growth hormone | SMALL ANIMAL | Endocrinology

Background Feline hypersomatotropism (HST) is a cause of diabetes mellitus in cats. Pasireotide is a novel multireceptor ligand somatostatin analog that improves biochemical control of humans with HST. Hypothesis/Objectives Pasireotide improves biochemical control of HST and diabetes mellitus in cats. Animals Hypersomatotropism was diagnosed in diabetic cats with serum insulin‐like growth factor‐1 (IGF‐1) concentration >1,000 ng/mL by radioimmunoassay and pituitary enlargement. Methods Insulin‐like growth factor 1 was measured and glycemic control assessed using a 12‐hour blood glucose curve on days 1 and 5. On days 2, 3, and 4, cats received 0.03 mg/kg pasireotide SC q12h. IGF‐1, insulin dose, and estimated insulin sensitivity (product of the area under the blood glucose curve [BGC] and insulin dose) were compared pre‐ and post treatment. Paired t‐tests or Wilcoxon signed rank tests were employed for comparison where appropriate; a linear mixed model was created to compare BGC results. Results Insulin‐like growth factor 1 decreased in all 12 cats that completed the study (median [range] day 1: 2,000 ng/mL [1,051–2,000] and day 5: 1,105 ng/mL [380–1,727], P = .002, Wilcoxon signed rank test). Insulin dose was lower on day 5 than on day 1 (mean reduction 1.3 [0–2.7] units/kg/injection, P = .003, paired t‐test). The product of insulin dose and area under the BGC was lower on day 5 than day 1 (difference of means: 1,912; SD, 1523; u × mg/dL × hours, P = .001; paired t‐test). No clinically relevant adverse effects were encountered. Conclusions Short‐acting pasireotide rapidly decreased IGF‐1 in cats with HST and insulin‐dependent diabetes. The decrease in IGF‐1 was associated with increased insulin sensitivity.
  • References (46)
    46 references, page 1 of 5

    1. Niessen SJM, Petrie G, Gaudiano F, et al. Feline acromegaly: An underdiagnosed endocrinopathy? J Vet Intern Med 2007;21:899-905.

    2. Meij BP, Auriemma E, Grinwis G, et al. Successful treatment of acromegaly in a diabetic cat with transsphenoidal hypophysectomy. J Feline Med Surg 2010;12:406-410.

    3. Niessen S. Feline Acromegaly: An essential differential diagnosis for the difficult diabetic. J Feline Med Surg 2010;12:15-23.

    4. Myers JA, Lunn KF, Bright JM. Echocardiographic Findings in 11 Cats with Acromegaly. J Vet Intern Med 2014;28:1235- 1238.

    5. Niessen SJM, Church DB, Forcada Y. Hypersomatotropism, acromegaly, and hyperadrenocorticism and feline diabetes mellitus. Vet Clin North Am Small Anim Pract 2013;43:319-350.

    6. Katznelson L, Laws ER, Melmed S, et al. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99:3933-3951.

    7. Taboada GF, Luque RM, Bastos W, et al. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 2007;156:65-74.

    8. Cuevas-Ramos D, Fleseriu M. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. J Mol Endocrinol 2014;52:R223-R240.

    9. Abraham L, Helmond S, Mitten RW, et al. Treatment of an acromegalic cat with the dopamine agonist L-deprenyl. Aust Vet J 2002;80:479-483.

    10. Slingerland LI, Voorhout G, Rijnberk A, Kooistra HS. Growth hormone excess and the effect of octreotide in cats with diabetes mellitus. Domest Anim Endocrinol 2008;35:352-361.

  • Metrics
    No metrics available
Share - Bookmark